Cargando…

Clinical efficacy of oral and topical acyclovir in herpes simplex virus stromal necrotizing keratitis

PURPOSE: To evaluate the efficacy of systemic and topical antiviral therapy in the treatment of active herpes simplex virus (HSV) necrotizing stromal keratitis (NSK). DESIGN: Prospective interventional case series. METHODOLOGY: Patients with a diagnosis of HSV NSK based on history and clinical findi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dutt, Surabhi, Acharya, Manisha, Gour, Abha, Sapra, Neelam, Chauhan, Lokesh, Mathur, Umang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4901847/
https://www.ncbi.nlm.nih.gov/pubmed/27221681
http://dx.doi.org/10.4103/0301-4738.182940
_version_ 1782436887411032064
author Dutt, Surabhi
Acharya, Manisha
Gour, Abha
Sapra, Neelam
Chauhan, Lokesh
Mathur, Umang
author_facet Dutt, Surabhi
Acharya, Manisha
Gour, Abha
Sapra, Neelam
Chauhan, Lokesh
Mathur, Umang
author_sort Dutt, Surabhi
collection PubMed
description PURPOSE: To evaluate the efficacy of systemic and topical antiviral therapy in the treatment of active herpes simplex virus (HSV) necrotizing stromal keratitis (NSK). DESIGN: Prospective interventional case series. METHODOLOGY: Patients with a diagnosis of HSV NSK based on history and clinical findings were enrolled in the study. A standard protocol was used for microbiologic investigations. Ten weeks regime of systemic acyclovir and 2 weeks of topical acyclovir was given. Complete ophthalmic examination was performed at every visit. Outcome measures were a reduction in the area of infiltration and improvement in visual acuity. RESULTS: Fifteen patients were enrolled in the study. The mean age of presentation was 51.53 years. The duration of symptoms at presentation ranged from 2 to 8 weeks. HSV1 DNA polymerase chain reaction was positive in 70% cases of those tested. Area of infiltration at trial entry and at the end of 2 weeks of antiviral treatment reduced significantly (P = 0.007). All patients showed a complete resolution of keratitis at the end of study. CONCLUSION: Topical and systemic acyclovir for treatment of NSK facilitates healing of ulceration. Topical steroids after initial antiviral therapy are safe and decreases inflammation and improve visual recovery. Early initiation of therapy has better outcomes as compared to late presentations.
format Online
Article
Text
id pubmed-4901847
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-49018472016-06-16 Clinical efficacy of oral and topical acyclovir in herpes simplex virus stromal necrotizing keratitis Dutt, Surabhi Acharya, Manisha Gour, Abha Sapra, Neelam Chauhan, Lokesh Mathur, Umang Indian J Ophthalmol Original Article PURPOSE: To evaluate the efficacy of systemic and topical antiviral therapy in the treatment of active herpes simplex virus (HSV) necrotizing stromal keratitis (NSK). DESIGN: Prospective interventional case series. METHODOLOGY: Patients with a diagnosis of HSV NSK based on history and clinical findings were enrolled in the study. A standard protocol was used for microbiologic investigations. Ten weeks regime of systemic acyclovir and 2 weeks of topical acyclovir was given. Complete ophthalmic examination was performed at every visit. Outcome measures were a reduction in the area of infiltration and improvement in visual acuity. RESULTS: Fifteen patients were enrolled in the study. The mean age of presentation was 51.53 years. The duration of symptoms at presentation ranged from 2 to 8 weeks. HSV1 DNA polymerase chain reaction was positive in 70% cases of those tested. Area of infiltration at trial entry and at the end of 2 weeks of antiviral treatment reduced significantly (P = 0.007). All patients showed a complete resolution of keratitis at the end of study. CONCLUSION: Topical and systemic acyclovir for treatment of NSK facilitates healing of ulceration. Topical steroids after initial antiviral therapy are safe and decreases inflammation and improve visual recovery. Early initiation of therapy has better outcomes as compared to late presentations. Medknow Publications & Media Pvt Ltd 2016-04 /pmc/articles/PMC4901847/ /pubmed/27221681 http://dx.doi.org/10.4103/0301-4738.182940 Text en Copyright: © Indian Journal of Ophthalmology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution NonCommercial ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Dutt, Surabhi
Acharya, Manisha
Gour, Abha
Sapra, Neelam
Chauhan, Lokesh
Mathur, Umang
Clinical efficacy of oral and topical acyclovir in herpes simplex virus stromal necrotizing keratitis
title Clinical efficacy of oral and topical acyclovir in herpes simplex virus stromal necrotizing keratitis
title_full Clinical efficacy of oral and topical acyclovir in herpes simplex virus stromal necrotizing keratitis
title_fullStr Clinical efficacy of oral and topical acyclovir in herpes simplex virus stromal necrotizing keratitis
title_full_unstemmed Clinical efficacy of oral and topical acyclovir in herpes simplex virus stromal necrotizing keratitis
title_short Clinical efficacy of oral and topical acyclovir in herpes simplex virus stromal necrotizing keratitis
title_sort clinical efficacy of oral and topical acyclovir in herpes simplex virus stromal necrotizing keratitis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4901847/
https://www.ncbi.nlm.nih.gov/pubmed/27221681
http://dx.doi.org/10.4103/0301-4738.182940
work_keys_str_mv AT duttsurabhi clinicalefficacyoforalandtopicalacyclovirinherpessimplexvirusstromalnecrotizingkeratitis
AT acharyamanisha clinicalefficacyoforalandtopicalacyclovirinherpessimplexvirusstromalnecrotizingkeratitis
AT gourabha clinicalefficacyoforalandtopicalacyclovirinherpessimplexvirusstromalnecrotizingkeratitis
AT sapraneelam clinicalefficacyoforalandtopicalacyclovirinherpessimplexvirusstromalnecrotizingkeratitis
AT chauhanlokesh clinicalefficacyoforalandtopicalacyclovirinherpessimplexvirusstromalnecrotizingkeratitis
AT mathurumang clinicalefficacyoforalandtopicalacyclovirinherpessimplexvirusstromalnecrotizingkeratitis